Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories and Mylan have reported that the novel beta blocker Bystolic was approved by the FDA for the treatment of hypertension.
Subscribe to our email newsletter
Bystolic is a once-daily medication that can be used alone or in combination with other hypertension treatments.
Forest licensed US and Canadian rights to Bystolic (nebivolol) from Mylan in January 2006. Forest will market Bystolic in the US and will pay Mylan undisclosed royalty payments as part of their collaboration agreement. Forest expects Bystolic to be available to physicians, patients and pharmacies in January 2008.
Howard Solomon, chairman and CEO of Forest, said: “We, along with our partner Mylan, are pleased to have received final FDA marketing approval for Bystolic. Bystolic represents an important advance for patients with hypertension and the physicians who treat them and will be an important new product for our company.”